At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.
Monogram Biosciences Inc. (NASDAQ: MGRM) is one of our highlighted companies this month. The Company is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs.
In the Company’s news today,
Monogram Biosciences Inc. announced that New York Medicaid has established coverage and reimbursement for the company’s Trofile Assay, a diagnostic used to determine whether or not a patient qualifies for Pfizer’s (NYSE: PFE) new HIV anti-viral medication Selzentry.
First identified in the United States in 1981, the AIDS epidemic has spread to every corner of the nation. In 1989, targeting New Yorkers who can’t afford medical care, the HIV Primary Care Medicaid Program revamped its reimbursement structure in recognition of the advances in HIV treatment and testing technology.
According to Bill Welch, Monogram’s Chief Commercial Officer, the number of people living with HIV/AIDS in many states, including New York, is staggering. “We are very pleased that New York Medicaid has established coverage for Trofile,” Welch stated in the press release. “Now the medical public assistance programs for the states with the largest numbers of residents living HIV/AIDS — namely California, Texas, Florida and New York — recognize the need and provide reimbursement for accurate tropism testing.”
The Medicaid coverage program will also be available from New York’s ADAP program, resulting in comprehensive coverage for all public payers in New York. “New York remains the epicenter of the HIV/AIDS epidemic in the U.S.,” Dennis deLeon, President of the Latino Commission on AIDS stated. “The state’s coverage and reimbursement of Trofile allows greater access to an advanced treatment option for the most vulnerable of our population living with HIV.”
Upon FDA approval of Pfizer’s Selzentry, Monogram introduced Trofile in August 2007. Since then, nearly 6,000 tests have been administered to patients throughout the United States. Trofile is now a covered benefit among 25 state Medicaid programs. It is also a covered benefit by Medicare, the Veteran’s Administration, the Corrections and Prison Systems and the Department of Indian Affairs, as well as a number of private payers.
About QualityStocks
QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net
